Piramal Pharma Limited (PPLPHARMA.NS)
INR 211.04
(-0.0%)
INR 211.04
(-0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 74 Billion INR | -4.5% |
| 2022 | 77.49 Billion INR | 261.94% |
| 2021 | 21.4 Billion INR | 29.28% |
| 2020 | 16.56 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 73.34 Billion INR | 192.71% |
| 2024 Q1 | -79.11 Billion INR | -206.9% |
| 2023 FY | 74 Billion INR | -4.5% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 74 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 70.17 Billion INR | 0.0% |
| 2022 Q2 | 69.98 Billion INR | 0.0% |
| 2022 FY | 77.49 Billion INR | 261.94% |
| 2022 Q4 | 77.49 Billion INR | 5.82% |
| 2022 Q3 | 73.23 Billion INR | 4.64% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 21.4 Billion INR | 0.0% |
| 2021 FY | 21.4 Billion INR | 29.28% |
| 2020 FY | 16.56 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 75.969% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | -3364.252% |
| Concord Biotech Limited | 1.74 Billion INR | -4151.587% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | -87.17% |
| Jubilant Ingrevia Limited | 19.94 Billion INR | -271.057% |
| Lyka Labs Limited | 884.58 Million INR | -8265.983% |
| Panacea Biotec Limited | 4.02 Billion INR | -1740.814% |
| SMS Lifesciences India Limited | 1.96 Billion INR | -3658.807% |
| Supriya Lifescience Limited | 1.05 Billion INR | -6890.12% |
| Syngene International Limited | 18.93 Billion INR | -290.751% |
| TAKE Solutions Limited | 969.78 Million INR | -7531.05% |
| Zota Health Care Limited | 1.38 Billion INR | -5248.998% |